Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash & Current Investments (2016 - 2025)

Zevra Therapeutics' Cash & Current Investments history spans 11 years, with the latest figure at $191.0 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 174.85% year-over-year to $191.0 million; the TTM value through Dec 2025 reached $191.0 million, up 174.85%, while the annual FY2025 figure was $191.0 million, 174.85% up from the prior year.
  • Cash & Current Investments reached $191.0 million in Q4 2025 per ZVRA's latest filing, down from $199.5 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $202.6 million in Q2 2025 to a low of $40.2 million in Q1 2023.
  • Average Cash & Current Investments over 5 years is $98.9 million, with a median of $82.7 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: soared 3122.28% in 2021, then crashed 60.44% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $112.3 million in 2021, then fell by 26.69% to $82.4 million in 2022, then decreased by 17.76% to $67.7 million in 2023, then grew by 2.6% to $69.5 million in 2024, then skyrocketed by 174.85% to $191.0 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Cash & Current Investments are $191.0 million (Q4 2025), $199.5 million (Q3 2025), and $202.6 million (Q2 2025).